Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 147

1.

Identification of the cytochrome P450 enzymes involved in the metabolism of cisapride: in vitro studies of potential co-medication interactions.

Bohets H, Lavrijsen K, Hendrickx J, van Houdt J, van Genechten V, Verboven P, Meuldermans W, Heykants J.

Br J Pharmacol. 2000 Apr;129(8):1655-67.

2.

Pharmacokinetics of lubeluzole (Prosynap) after single intravenous doses in healthy subjects.

Van de Velde V, Crabbe R, Van Peer A, Woestenborghs R, Van Osselaer N, Hantson L, Heykants J.

Int J Clin Pharmacol Ther. 1998 Sep;36(9):490-3.

PMID:
9760010
3.

Population analysis of the non linear red blood cell partitioning and the concentration-effect relationship of draflazine following various infusion rates.

Snoeck E, Piotrovskij V, Jacqmin P, Van Peer A, Danhof M, Ver Donck K, Woestenborghs R, Van Belle H, Van Bortel L, Van Gool R, Dupont AG, Heykants J.

Br J Clin Pharmacol. 1997 Jun;43(6):603-12.

4.

Population analysis of the non-linear red blood cell partitioning of draflazine following various infusion durations.

Snoeck E, Piotrovskij V, Jacqmin P, Lins RL, Van Peer A, Danhof M, Woestenborghs R, Van Gool R, Dupont AG, Heykants J.

Eur J Clin Pharmacol. 1997;53(1):57-63.

PMID:
9349931
5.

The implications of non-linear red blood cell partitioning for the pharmacokinetics and pharmacodynamics of the nucleoside transport inhibitor draflazine.

Snoeck E, Jacqmin P, Van Peer A, Danhof M, Ver Donck K, Van Belle H, Woestenborghs R, Crabbé R, Van Gool R, Dupont A, Heykants J.

Br J Clin Pharmacol. 1996 Nov;42(5):605-13.

6.

Effect of food on the pharmacokinetics of a new hydroxypropyl-beta-cyclodextrin formulation of itraconazole.

Van de Velde VJ, Van Peer AP, Heykants JJ, Woestenborghs RJ, Van Rooy P, De Beule KL, Cauwenbergh GF.

Pharmacotherapy. 1996 May-Jun;16(3):424-8.

PMID:
8726601
7.
8.

Influence of age, renal and liver impairment on the pharmacokinetics of risperidone in man.

Snoeck E, Van Peer A, Sack M, Horton M, Mannens G, Woestenborghs R, Meibach R, Heykants J.

Psychopharmacology (Berl). 1995 Dec;122(3):223-9.

PMID:
8748391
9.

Linearity of pharmacokinetics and model estimation of sufentanil.

Gepts E, Shafer SL, Camu F, Stanski DR, Woestenborghs R, Van Peer A, Heykants JJ.

Anesthesiology. 1995 Dec;83(6):1194-204.

PMID:
8533912
10.

The pharmacokinetic properties of topical levocabastine. A review.

Heykants J, Van Peer A, Van de Velde V, Snoeck E, Meuldermans W, Woestenborghs R.

Clin Pharmacokinet. 1995 Oct;29(4):221-30. Review.

PMID:
8549024
11.

Reduction of the prodrug loperamide oxide to its active drug loperamide in the gut of rats, dogs, and humans.

Lavrijsen K, van Dyck D, van Houdt J, Hendrickx J, Monbaliu J, Woestenborghs R, Meuldermans W, Heykants J.

Drug Metab Dispos. 1995 Mar;23(3):354-62.

PMID:
7628301
12.

Gastrointestinal distribution of the prodrug loperamide oxide and its active drug loperamide in the dog.

Van Beijsterveldt LE, Geerts RJ, Wuyts K, Woestenborghs RJ, Meuldermans WE, Heykants JJ.

Drug Metab Dispos. 1995 Feb;23(2):216-22.

PMID:
7736914
13.

Plasma protein binding of risperidone and its distribution in blood.

Mannens G, Meuldermans W, Snoeck E, Heykants J.

Psychopharmacology (Berl). 1994 May;114(4):566-72.

PMID:
7531854
14.

The pharmacokinetics of risperidone in humans: a summary.

Heykants J, Huang ML, Mannens G, Meuldermans W, Snoeck E, Van Beijsterveldt L, Van Peer A, Woestenborghs R.

J Clin Psychiatry. 1994 May;55 Suppl:13-7.

PMID:
7520903
15.

Assay methods for sufentanil in plasma. Radioimmunoassay versus gas chromatography-mass spectrometry.

Woestenborghs RJ, Timmerman PM, Cornelissen ML, Van Rompaey FA, Gepts E, Camu F, Heykants JJ, Stanski DR.

Anesthesiology. 1994 Mar;80(3):666-70.

PMID:
8141462
16.

Regional brain distribution of risperidone and its active metabolite 9-hydroxy-risperidone in the rat.

van Beijsterveldt LE, Geerts RJ, Leysen JE, Megens AA, Van den Eynde HM, Meuldermans WE, Heykants JJ.

Psychopharmacology (Berl). 1994 Feb;114(1):53-62.

PMID:
7531352
17.

The metabolism and excretion of risperidone after oral administration in rats and dogs.

Meuldermans W, Hendrickx J, Mannens G, Lavrijsen K, Janssen C, Bracke J, Le Jeune L, Lauwers W, Heykants J.

Drug Metab Dispos. 1994 Jan-Feb;22(1):129-38.

PMID:
7512019
18.

Pharmacokinetics of orally administered levocabastine in patients with renal insufficiency.

Zazgornik J, Huang ML, Van Peer A, Woestenborghs R, Heykants J, Stephen A.

J Clin Pharmacol. 1993 Dec;33(12):1214-8.

PMID:
7907347
19.

Absorption, metabolism, and excretion of risperidone in humans.

Mannens G, Huang ML, Meuldermans W, Hendrickx J, Woestenborghs R, Heykants J.

Drug Metab Dispos. 1993 Nov-Dec;21(6):1134-41.

PMID:
7507814
20.

Discrepancies in bioassay and chromatography determinations explained by metabolism of itraconazole to hydroxyitraconazole: studies of interpatient variations in concentrations.

Hostetler JS, Heykants J, Clemons KV, Woestenborghs R, Hanson LH, Stevens DA.

Antimicrob Agents Chemother. 1993 Oct;37(10):2224-7.

21.

Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects.

Huang ML, Van Peer A, Woestenborghs R, De Coster R, Heykants J, Jansen AA, Zylicz Z, Visscher HW, Jonkman JH.

Clin Pharmacol Ther. 1993 Sep;54(3):257-68.

PMID:
7690693
22.

Insufficient ketoconazole concentrations in preterm infants with fungal infections.

van den Anker JN, van Lingen RA, Koster M, Heykants J, Sauer PJ.

Eur J Pediatr. 1993 Jun;152(6):538. No abstract available.

PMID:
8335029
23.

Pharmacokinetic-pharmacodynamic relationships in phase I/phase II of drug development.

Van Peer A, Snoeck E, Huang ML, Heykants J.

Eur J Drug Metab Pharmacokinet. 1993 Jan-Mar;18(1):49-59. Review.

PMID:
8335039
24.

Determination of risperidone and 9-hydroxyrisperidone in plasma, urine and animal tissues by high-performance liquid chromatography.

Woestenborghs R, Lorreyne W, Van Rompaey F, Heykants J.

J Chromatogr. 1992 Dec 2;583(2):223-30.

PMID:
1282517
25.

Stimulation by risperidone of rat prolactin secretion in vivo and in cultured pituitary cells in vitro.

Bowden CR, Voina SJ, Woestenborghs R, De Coster R, Heykants J.

J Pharmacol Exp Ther. 1992 Aug;262(2):699-706.

PMID:
1380082
26.

Comparative metabolism of flunarizine in rats, dogs and man: an in vitro study with subcellular liver fractions and isolated hepatocytes.

Lavrijsen K, van Houdt J, van Dyck D, Hendrickx J, Bockx M, Hurkmans R, Meuldermans W, Le Jeune L, Lauwers W, Heykants J.

Xenobiotica. 1992 Jul;22(7):815-36.

PMID:
1455902
27.

Posttreatment itraconazole levels in the nail. New implications for treatment in onychomycosis.

Willemsen M, De Doncker P, Willems J, Woestenborghs R, Van de Velde V, Heykants J, Van Cutsem J, Cauwenbergh G, Roseeuw D.

J Am Acad Dermatol. 1992 May;26(5 Pt 1):731-5.

PMID:
1316389
28.

A predictive model for substrates of cytochrome P450-debrisoquine (2D6).

Koymans L, Vermeulen NP, van Acker SA, te Koppele JM, Heykants JJ, Lavrijsen K, Meuldermans W, Donné-Op den Kelder GM.

Chem Res Toxicol. 1992 Mar-Apr;5(2):211-9.

PMID:
1379482
29.

Pharmacokinetics of ritanserin in patients undergoing hemodialysis.

Zazgornik J, Kuska J, Kokot F, Koch S, Van Peer A, Huang ML, Heykants J.

J Clin Pharmacol. 1991 Jul;31(7):657-61.

PMID:
1910052
30.

Clinical pharmacokinetics of ketanserin.

Persson B, Heykants J, Hedner T.

Clin Pharmacokinet. 1991 Apr;20(4):263-79. Review.

PMID:
2036747
31.

Study of the placental transfer of cisapride in sheep. Plasma levels in the pregnant ewe, the fetus, and the lamb.

Veereman-Wauters G, Monbaliu J, Meuldermans W, Woestenborghs R, Verlinden M, Heykants J, Rudolph CD.

Drug Metab Dispos. 1991 Jan-Feb;19(1):168-72.

PMID:
1673393
32.

Biotransformation of sufentanil in liver microsomes of rats, dogs, and humans.

Lavrijsen K, Van Houdt J, Van Dyck D, Hendrickx J, Lauwers W, Hurkmans R, Bockx M, Janssen C, Meuldermans W, Heykants J.

Drug Metab Dispos. 1990 Sep-Oct;18(5):704-10.

PMID:
1981724
33.

Pharmacokinetics of oral antifungals and their clinical implications.

Heykants J, Van Peer A, Lavrijsen K, Meuldermans W, Woestenborghs R, Cauwenbergh G.

Br J Clin Pract Suppl. 1990 Sep;71:50-6. Review.

PMID:
1965419
34.

Alfentanil pharmacokinetics in preterm infants.

Marlow N, Weindling AM, Van Peer A, Heykants J.

Arch Dis Child. 1990 Apr;65(4 Spec No):349-51.

35.

Induction potential of fluconazole toward drug-metabolizing enzymes in rats.

Lavrijsen KL, Van Houdt JM, Van Dyck DM, Meuldermans WE, Heykants JJ.

Antimicrob Agents Chemother. 1990 Mar;34(3):402-8.

36.

Levels of itraconazole in skin blister fluid after a single oral dose and during repetitive administration.

Schäfer-Korting M, Korting HC, Lukacs A, Heykants J, Behrendt H.

J Am Acad Dermatol. 1990 Feb;22(2 Pt 1):211-5.

PMID:
2155951
37.

Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives.

Pauwels R, Andries K, Desmyter J, Schols D, Kukla MJ, Breslin HJ, Raeymaeckers A, Van Gelder J, Woestenborghs R, Heykants J, et al.

Nature. 1990 Feb 1;343(6257):470-4.

PMID:
1689015
38.

Comparative bioavailability of a cisapride suppository and tablet formulation in healthy volunteers.

Hedner T, Hedner J, Gelin-Friberg A, Huang ML, Van de Poel S, Woestenborghs R, Van Peer A, Heykants J.

Eur J Clin Pharmacol. 1990;38(6):629-31.

PMID:
2373139
39.

On the terrestrial toxicity of the fungicide imazalil (enilconazole) to the earthworm species Eisenia foetida.

Van Leemput L, Swysen E, Woestenborghs R, Michielsen L, Meuldermans W, Heykants J.

Ecotoxicol Environ Saf. 1989 Dec;18(3):313-20.

PMID:
2612423
40.

Narcotic analgesics and debrisoquine polymorphism.

Lavrijsen KL, Heykants JJ.

Anesthesiology. 1989 Sep;71(3):474-5. No abstract available.

PMID:
2570539
41.

Deuterated ritanserin analysis by gas chromatography/mass spectrometry: a sensitive technique to study human ritanserin pharmacokinetics.

Timmerman P, Woestenborghs R, Lenoir H, Heykants J.

Biomed Environ Mass Spectrom. 1989 Jul;18(7):498-502.

PMID:
2505878
42.

Pharmacokinetics of alfentanil during and after a fixed rate infusion.

Van Beem H, Van Peer A, Gasparini R, Woestenborghs R, Heykants J, Noorduin H, Van Egmond J, Crul J.

Br J Anaesth. 1989 Jun;62(6):610-5.

43.

Skin blister fluid levels of ketoconazole during repetitive administration in healthy man.

Korting HC, Lukacs A, Schäfer-Korting M, Heykants J, Behrendt H.

Mycoses. 1989 Jan;32(1):39-45.

PMID:
2747741
44.

The clinical pharmacokinetics of itraconazole: an overview.

Heykants J, Van Peer A, Van de Velde V, Van Rooy P, Meuldermans W, Lavrijsen K, Woestenborghs R, Van Cutsem J, Cauwenbergh G.

Mycoses. 1989;32 Suppl 1:67-87. Review.

PMID:
2561187
45.

The effects of food and dose on the oral systemic availability of itraconazole in healthy subjects.

Van Peer A, Woestenborghs R, Heykants J, Gasparini R, Gauwenbergh G.

Eur J Clin Pharmacol. 1989;36(4):423-6.

PMID:
2544431
46.

Is the metabolism of alfentanil subject to debrisoquine polymorphism? A study using human liver microsomes.

Lavrijsen KL, Van Houdt JM, Van Dyck DM, Hendrickx JJ, Woestenborghs RJ, Lauwers W, Meuldermans WE, Heykants JJ.

Anesthesiology. 1988 Oct;69(4):535-40.

PMID:
3140691
47.

Alfentanil pharmacokinetics and metabolism in humans.

Meuldermans W, Van Peer A, Hendrickx J, Woestenborghs R, Lauwers W, Heykants J, Vanden Bussche G, Van Craeyvelt H, Van der Aa P.

Anesthesiology. 1988 Oct;69(4):527-34.

PMID:
3140690
48.

Itraconazole pharmacokinetics in patients with renal dysfunction.

Boelaert J, Schurgers M, Matthys E, Daneels R, van Peer A, De Beule K, Woestenborghs R, Heykants J.

Antimicrob Agents Chemother. 1988 Oct;32(10):1595-7.

49.

Essential tremor and flunarizine.

Amery WK, Heykants J.

Cephalalgia. 1988 Sep;8(3):227. No abstract available.

PMID:
3197103
50.

Pharmacokinetics of droperidol in surgical patients under different conditions of anaesthesia.

Lehmann KA, Van Peer A, Ikonomakis M, Gasparini R, Heykants J.

Br J Anaesth. 1988 Sep;61(3):297-301.

Supplemental Content

Loading ...
Support Center